Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.

Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K.

MAbs. 2013 Mar-Apr;5(2):229-36. doi: 10.4161/mabs.23452. Epub 2013 Feb 13.

2.

Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.

Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K.

Mol Immunol. 2014 Mar;58(1):132-8. doi: 10.1016/j.molimm.2013.11.017. Epub 2013 Dec 14.

3.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
4.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
5.

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.

Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, Sweet H, Foltz I, Howard M, Rousseau AM, Kozlosky C, Fanslow W, Yan W.

J Biol Chem. 2014 Feb 7;289(6):3571-90. doi: 10.1074/jbc.M113.513366. Epub 2013 Dec 5.

6.

Engineered antibody Fc variants with enhanced effector function.

Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10. Epub 2006 Mar 6.

7.

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.

Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A.

MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15.

8.

Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.

Ahmed AA, Keremane SR, Vielmetter J, Bjorkman PJ.

J Struct Biol. 2016 Apr;194(1):78-89. doi: 10.1016/j.jsb.2016.02.001. Epub 2016 Feb 2.

9.

Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.

Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T.

PLoS One. 2015 Dec 11;10(12):e0143520. doi: 10.1371/journal.pone.0143520. eCollection 2015.

10.
11.

IgG2m4, an engineered antibody isotype with reduced Fc function.

An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, Harvey BR, Montgomery D, Zaller D, Wang F, Strohl W.

MAbs. 2009 Nov-Dec;1(6):572-9.

12.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

13.

Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.

Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K.

Mol Immunol. 2007 May;44(12):3122-31. Epub 2007 Mar 26.

PMID:
17379311
14.

A variant human IgG1-Fc mediates improved ADCC.

Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM, Webster C, Jermutus L, Lund J.

Protein Eng Des Sel. 2011 Sep;24(9):671-8. doi: 10.1093/protein/gzr015. Epub 2011 May 18.

PMID:
21596686
15.

Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.

Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.

J Immunol Methods. 2011 Feb 28;365(1-2):132-41. doi: 10.1016/j.jim.2010.12.014. Epub 2010 Dec 23.

PMID:
21185301
16.

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).

Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K.

Protein Eng Des Sel. 2013 Oct;26(10):589-98. doi: 10.1093/protein/gzt022. Epub 2013 Jun 5.

17.

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.

Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M.

MAbs. 2014 Mar-Apr;6(2):409-21. doi: 10.4161/mabs.27457. Epub 2013 Dec 11.

18.

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, Bailey-Kellogg C, Ackerman ME, Scanlan C, Zolla-Pazner S, Alter G.

AIDS. 2014 Nov 13;28(17):2523-30. doi: 10.1097/QAD.0000000000000444.

19.

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, Vanderlaan M, Song A.

MAbs. 2012 May-Jun;4(3):326-40. doi: 10.4161/mabs.19941. Epub 2012 Apr 26.

20.

An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.

Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ.

MAbs. 2015;7(3):494-504. doi: 10.1080/19420862.2015.1022692.

Supplemental Content

Support Center